These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22446059)

  • 21. Effects of the cognition impairer MK-801 on learning and memory in mice and rats.
    van der Staay FJ; Rutten K; Erb C; Blokland A
    Behav Brain Res; 2011 Jun; 220(1):215-29. PubMed ID: 21310186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basal Ganglia accumulation and motor assessment following manganese chloride exposure in the C57BL/6 mouse.
    Dodd CA; Ward DL; Klein BG
    Int J Toxicol; 2005; 24(6):389-97. PubMed ID: 16393931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
    Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
    Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.
    Ahmad M; Yousuf S; Khan MB; Hoda MN; Ahmad AS; Ansari MA; Ishrat T; Agrawal AK; Islam F
    Pharmacol Biochem Behav; 2006 Jan; 83(1):150-60. PubMed ID: 16500697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
    Mignon L; Wolf WA
    Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sleep deprivation induces late deleterious effects in a pharmacological model of Parkinsonism.
    Lopes-Silva LB; Cunha DMG; Lima AC; Bioni VS; Gonçalves N; Kurita JPF; Wuo-Silva R; Silva RH
    Exp Brain Res; 2024 May; 242(5):1175-1190. PubMed ID: 38499659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
    Lee J; Di Marzo V; Brotchie JM
    Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model.
    Baluchnejadmojarad T; Roghani M; Nadoushan MR; Bagheri M
    Phytother Res; 2009 Jan; 23(1):132-5. PubMed ID: 18693302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
    Ulusoy GK; Celik T; Kayir H; Gürsoy M; Isik AT; Uzbay TI
    Brain Res Bull; 2011 Jul; 85(6):380-4. PubMed ID: 21600965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Female Rats Are Resistant to Cognitive, Motor and Dopaminergic Deficits in the Reserpine-Induced Progressive Model of Parkinson's Disease.
    Lima AC; Meurer YSR; Bioni VS; Cunha DMG; Gonçalves N; Lopes-Silva LB; Becegato M; Soares MBL; Marinho GF; Santos JR; Silva RH
    Front Aging Neurosci; 2021; 13():757714. PubMed ID: 34759815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temporal development of neurochemical and cognitive impairments following reserpine administration in rats.
    Pereira AG; Poli A; Matheus FC; de Bortoli da Silva L; Fadanni GP; Izídio GS; Latini A; Prediger RD
    Behav Brain Res; 2020 Apr; 383():112517. PubMed ID: 32006562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
    Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
    Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression.
    Leão AH; Meurer YS; da Silva AF; Medeiros AM; Campêlo CL; Abílio VC; Engelberth RC; Cavalcante JS; Izídio GS; Ribeiro AM; Silva RH
    Front Aging Neurosci; 2017; 9():78. PubMed ID: 28396635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.
    Hsieh MH; Gu SL; Ho SC; Pawlak CR; Lin CL; Ho YJ; Lai TJ; Wu FY
    Behav Brain Res; 2012 Apr; 229(1):41-7. PubMed ID: 22227506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
    Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
    Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant effects of 4-aminopyridine and tetraethylammonium in the treatment of 6-hydroxydopamine-induced Parkinson's disease.
    Haghdoost-Yazdi H; Faraji A; Fraidouni N; Movahedi M; Hadibeygi E; Vaezi F
    Behav Brain Res; 2011 Sep; 223(1):70-4. PubMed ID: 21540059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
    Silverdale MA; McGuire S; McInnes A; Crossman AR; Brotchie JM
    Exp Neurol; 2001 Jun; 169(2):400-6. PubMed ID: 11358453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.